Philadelphia’s Medicus Pharma Closes $4.25 Million CEO-Led Financing and $10.5 Million Debt Exchange

Published · 6 min read · Greater Philadelphia
Philadelphia’s Medicus Pharma Closes $4.25 Million CEO-Led Financing and $10.5 Million Debt Exchange

Medicus Pharma, a Philadelphia-based biotechnology company advancing clinical-stage drug candidates in oncology and other areas, has closed $4.25 million in equity financings and exchanged $10.5 million of debt for preferred shares, the company announced on November 16, 2026. The financing was led by company insiders, including $750,000 from Dr. Raza Bokhari, Medicus’ Executive Chairman and Chief Executive Officer.

Inside the Financing

The $4.25 million came from two offerings, both priced at $1.72 per share. A private placement of 726,730 common shares raised $1.25 million, mostly from the company’s directors and officers. A registered direct offering raised about $3.0 million through 97,973 common shares plus pre-funded warrants to buy up to 1,646,213 more shares. Maxim Group LLC served as financial advisor on the registered direct offering.

Medicus says the proceeds will provide working capital for its operating and development priorities, including advancing CD228V, its lead oncology program. Some of the money may also go toward paying down debt.

Through the private placement, Dr. Bokhari acquired 436,046 shares indirectly through RBx Capital LP, an entity he controls. His beneficial ownership rose from about 3.8% to about 18.3% of Medicus’ outstanding common shares.

Debt Exchange and Nasdaq Listing

Separately, Streeterville Capital, LLC exchanged $10.5 million of debt held under Medicus’ secured promissory notes for 105,000 preferred shares, issued at $100 each. The preferred shares carry an 8% annual dividend paid in additional shares. They are non-voting and can’t be converted into common stock, and Medicus can choose to redeem them. The exchange didn’t bring in any cash, and any debt not exchanged remains outstanding.

Medicus believes the financings, the debt exchange, and about $350,000 in additional share sales since September 30 have lifted its shareholders’ equity above Nasdaq’s $2.5 million minimum for continued listing. The company says it has regained compliance with that rule, subject to Nasdaq’s confirmation.

About Medicus Pharma

Medicus develops clinical-stage drug candidates through Phase 2 proof-of-concept, with the goal of partnering them with larger pharmaceutical companies. Its lead program, CD228V, is an investigational antibody-drug conjugate built on Pfizer’s vedotin linker-payload platform. It targets CD228, a protein found on several solid tumors, including melanoma, squamous non-small cell lung cancer, head and neck cancer, and esophageal cancer. Medicus is also developing SkinJect®, an investigational treatment for basal cell carcinoma lesions in patients with Gorlin syndrome, and Teverelix®, an investigational GnRH antagonist for advanced prostate cancer in patients at high cardiovascular risk, recurrent urinary retention due to an enlarged prostate, and endometriosis.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s financial performance and business outlook, the equity financing and the debt exchange, including the anticipated use of proceeds, the anticipated accounting treatment of the preferred shares as permanent equity, the Company’s pro forma shareholders’ equity, the Company’s belief that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), any determination by Nasdaq regarding the Company’s compliance, the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the planned initiation, timing, design, conduct and results of the SKNJCT-005 registrational study in patients with Gorlin Syndrome, the projected cost of the SkinJect® development program, the Company’s decision to develop SkinJect® exclusively for patients with Gorlin Syndrome, the timing and outcome of the FDA’s review of the Company’s Orphan Drug Designation and Rare Pediatric Disease Designation applications for SkinJect®, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer (“APC”), women’s health indications like endometriosis, the FDA’s feedback regarding the Company’s Phase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed design of the Phase 2b/3 registration-intent program, the potential to reduce the overall planned APC clinical development program from approximately 1,500 patients to approximately 600 patients, the establishment of a defined, capital-efficient and partner-ready registrational pathway for Teverelix® without Medicus independently funding an additional APC clinical development study, Medicus’ intent and ability to out-license or otherwise strategically partner the Teverelix® APC program, the anticipated completion of GMP-grade manufacturing, quality-release and other clinical study readiness steps, whether the proposed cardiovascular-focused registrational strategy, including the 12-month non-calcified coronary plaque endpoint assessed using non-invasive coronary CCTA and the evaluation of Teverelix® effects on APC patients at increased cardiovascular risk, could support registration, the Company’s capital-efficient portfolio strategy and the anticipated benefits thereof, the anticipated reduction in the Company’s operating expenses, the Company’s view that SkinJect® and Teverelix® are partner-ready programs, the Company’s co-development and license agreement with Pfizer with respect to CD228V, the Company’s strategy relating thereto and the anticipated benefits thereof, including whether Pfizer elects to fund any development activities for CD228V and whether the parties enter into a definitive agreement in respect thereof, the Company’s ability to identify, negotiate and complete partnerships, licensing, co-development or other strategic transactions and the timing, terms and anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the Company’s plans to prioritize clinical proof-of-concept for CD228V in melanoma, including relapsed, refractory or immunotherapy-resistant disease, the potential for CD228V to achieve an objective response rate exceeding 30% in melanoma and to support a future monotherapy registration strategy, the potential for biomarker research to guide development, the potential for evidence generated in melanoma to support evaluation of CD228V in additional CD228-expressing solid tumors, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “goal”, “strive”, “prioritize”, “pursue”, “intended”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2025, as amended, and its quarterly report on Form 10-Q for the quarter ended September 30, 2026, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer (610) 636-0184 [email protected]

Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162 [email protected]

Source: B2i, Medicus Pharma on November 16, 2026. Republished with credit to the original author. Read the original release.